• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Akumin Inc. Completes Deleveraging Transaction, Becomes a Private Company Wholly-Owned by Stonepeak

    2/6/24 6:26:00 PM ET
    $AKU
    Medical Specialities
    Health Care
    Get the next $AKU alert in real time by email

    Akumin well-positioned to continue providing top-quality radiology and oncology services to patients, health systems, hospitals, and physician groups across the U.S.

    PLANTATION, Fla., Feb. 6, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") today announced that it has completed its deleveraging transaction, becoming a private company wholly-owned by Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets. The deleveraging and recapitalization transaction was implemented through a voluntary, court-supervised financial restructuring process, which is now complete.

    "We are pleased to have concluded this process and are excited to enter our next chapter as a private company in partnership with Stonepeak," said Riadh Zine, Chairman and Chief Executive Officer of Akumin. "We are emerging from this process with significant positive momentum across our business, and in our view, we are better positioned than ever to execute on our strategic plan and drive our future success. With increased financial flexibility and Stonepeak's strong support, we will be able to continue to invest in our business by upgrading equipment, deploying new service delivery technologies and renovating facilities in support of our objective to become the outpatient service provider of choice for patients, health systems and hospital partners in Radiology and Oncology."

    "This milestone is a testament to our employees' hard work and their relentless commitment to our mission," Mr. Zine continued. "The leadership team and I are greatly appreciative of the unfailing support we received from all of Akumin's stakeholders as we worked through this process over the last few months."

    "Akumin is now well-positioned to take the next step in its journey as a leading provider of critical health services and trusted partner to patients, health systems, hospitals, and physician groups nationwide with a streamlined capital structure in place," said Graham Brown, Managing Director at Stonepeak. "We look forward to leveraging our resources and expertise as we work alongside Akumin's talented team to support the company's continued progress and mission with the objective of enhancing patient experiences and outcomes."

    In connection with the close of the transaction, Akumin's stock has been delisted from the Toronto Stock Exchange and OTC Pink Open Market.

    Akumin's advisors include Jackson Walker LLP, Dorsey & Whitney LLP, Stikeman Elliott LLP and McDermott Will & Emery LLP as legal advisors , AlixPartners LLP as financial advisor, and Leerink Partners LLC as investment banker. Sidley Austin LLP is serving as legal advisor to Stonepeak, and Moelis & Company LLC is serving as Stonepeak's investment banker.

    About Akumin

    Akumin is a national outpatient partner of choice for U.S. hospitals, health systems and physician groups, addressing their outsourced radiology and oncology needs. Akumin provides comprehensive radiology and oncology services and solutions to approximately 1,000 hospitals and health systems across 47 states, and offers fixed-site outpatient diagnostic imaging through a network of owned and/or operated facilities. By combining clinical and operational expertise with the latest advances in technology and informatics, Akumin delivers unparalleled patient experiences and outcomes. Our radiology procedures include MRI, CT, PET/CT, ultrasound, 3D mammography, X-ray, and other interventional procedures; our oncology services include a full suite of radiation therapy and related offerings. For more information, visit www.akumin.com.

    About Stonepeak

    Stonepeak is a leading alternative investment firm specializing in infrastructure and real assets with approximately $61.1 billion of assets under management. Through its investment in defensive, hard-asset businesses globally, Stonepeak aims to create value for its investors and portfolio companies, with a focus on downside protection and strong risk-adjusted returns. Stonepeak sponsors investment vehicles focused on private equity and credit. The firm provides capital, operational support, and committed partnership to grow investments in its target sectors, which include communications, energy and energy transition, transport and logistics, social infrastructure, and real estate. Stonepeak is headquartered in New York with offices in Hong Kong, Houston, London, Singapore, and Sydney. For more information, please visit www.stonepeak.com.

    SOURCE Akumin Inc.

    Cision View original content: http://www.newswire.ca/en/releases/archive/February2024/06/c1055.html

    Get the next $AKU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKU

    DatePrice TargetRatingAnalyst
    11/14/2022$3.50 → $3.00Buy → Speculative Buy
    Canaccord Genuity
    More analyst ratings

    $AKU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

      SC 13G/A - AKUMIN INC. (0001776197) (Subject)

      2/12/24 4:37:41 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Akumin Inc.

      SC 13G - AKUMIN INC. (0001776197) (Subject)

      2/12/24 4:31:27 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

      SC 13G/A - AKUMIN INC. (0001776197) (Subject)

      2/7/24 10:43:55 AM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Akumin downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Akumin from Buy to Speculative Buy and set a new price target of $3.00 from $3.50 previously

      11/14/22 8:59:34 AM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Leadership Updates

    Live Leadership Updates

    See more
    • AKUMIN ANNOUNCES LEADERSHIP TRANSITION

      PLANTATION, Fla., Dec. 29, 2023 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its Board of Directors has appointed Ronald J. Bienias, Akumin's Chief Restructuring Officer and Partner and Managing Director of AlixPartners, LLP, as Interim Chief Financial Officer, effective today. He will also maintain his current role as Chief Restructuring Officer. Ronald's appointment follows the resignation of David Kretschmer, as Akumin's Chief Financial Officer effective today. Ronald has more than 20 years of experience serving in interim leadership roles or as an advisor at both large and

      12/29/23 7:52:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Announces Change of Auditor

      PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) announced today that it has changed its auditor from Ernst & Young LLP ("EY") to Deloitte & Touche LLP ("Deloitte"). Effective as of August 9, 2023, the audit committee (the "Audit Committee") of the board of directors (the "Board") of the Company dismissed EY as the Company's independent registered public accounting firm. EY audited the Company's financial statements for each of the past two fiscal years ended December 31, 2022 and 2021, and EY's reports did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or

      8/9/23 5:31:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin appoints President and Chief Operating Officer

      PLANTATION, Fla., June 12, 2023 /CNW/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) today announced the appointment of Krishna Kumar as President and Chief Operating Officer of the Company, effective as of June 16, 2023. Krishna has valuable experience and exceptional insight into the radiology space, having served as Senior Vice President & Business Leader - Precision Diagnosis at Philips North America, where he built a top performing team and business, over the last four years. Prior to this role, he led global businesses in Pathology, Oncology and Neuro at Philips based in Amsterdam, Netherlands from 2015-2019 and prior thereto was the CEO of Philips India. Before joini

      6/12/23 6:59:57 AM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akumin Announces Changes to Leadership Team

      Krishna Kumar, Current President & Chief Operating Officer, Appointed Chief Executive Officer Chandra Westergaard Named General Counsel PLANTATION, Fla., Feb. 8, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") announced today that Krishna Kumar, who has served as President and Chief Operating Officer at the Company, has been appointed Chief Executive Officer, effective immediately. He succeeds Riadh Zine, Akumin's Founder, who is stepping down as Chairman and Chief Executive Officer. Akumin also announced that Chandra Westergaard has been named General Counsel and will oversee the Company's legal and compliance functions. "On behalf of Akumin, I would like to thank Riadh for his dedica

      2/8/24 5:00:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Inc. Completes Deleveraging Transaction, Becomes a Private Company Wholly-Owned by Stonepeak

      Akumin well-positioned to continue providing top-quality radiology and oncology services to patients, health systems, hospitals, and physician groups across the U.S. PLANTATION, Fla., Feb. 6, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") today announced that it has completed its deleveraging transaction, becoming a private company wholly-owned by Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets. The deleveraging and recapitalization transaction was implemented through a voluntary, court-supervised financial restructuring process, which is now complete. "We are pleased to have concluded this process and are excited to enter our next chapt

      2/6/24 6:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Inc. Provides Update on its Restructuring Transaction

      /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

      1/31/24 10:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Foursixthree Capital Lp claimed ownership of 10,556,851 shares (SEC Form 3)

      3 - AKUMIN INC. (0001776197) (Issuer)

      2/5/24 4:50:02 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Bienias Ronald J.

      3 - AKUMIN INC. (0001776197) (Issuer)

      10/26/23 10:40:46 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Kumar Krishna

      4 - AKUMIN INC. (0001776197) (Issuer)

      7/18/23 1:31:57 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Financials

    Live finance-specific insights

    See more
    • Akumin Inc. Provides Update on its Restructuring Transaction

      /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

      1/31/24 10:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Announces Second Quarter 2023 Results, Revised FY23 Financial Outlook and Establishment of Special Committee

      PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company"), a national partner of choice for U.S. hospitals, health systems and physician groups, with comprehensive solutions addressing outsourced radiology and oncology service-line needs, announced today its financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Akumin delivered second quarter same-store volume performance on a consolidated basis as follows:+3.1% for MRI+16.5% for PET/CT+3.4% for Oncology Patient StartsThe Company reported revenue totaling $184.8 million for the second quarter, a $7.3 million or 4% decrease over the second quarter of last year.

      8/9/23 5:23:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin to Host Second Quarter 2023 Financial Results Call on August 10, 2023

      PLANTATION, Fla., Aug. 8, 2023 /PRNewswire/ - Akumin Inc. (TSX:AKU) ("Akumin" or the "Company") will host a conference call at 8:30 a.m. Eastern Time, Thursday, August 10, 2023, to discuss its second quarter 2023 financial results.  The financial results are expected to be available on Wednesday, August 9, 2023. To access the conference call, participants may join by using an appropriate dial-in number available through https://akum.in/Q2-2023-Results-Dial-In-Numbers or via webcast at https://akum.in/Q2-2023-Results-Webcast. A related presentation will be available from Akumin's website (www.akumin.com). Participants are asked to connect at least 10 minutes prior to the beginning of the call

      8/8/23 5:23:00 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    SEC Filings

    See more
    • SEC Form EFFECT filed by Akumin Inc.

      EFFECT - AKUMIN INC. (0001776197) (Filer)

      2/13/24 12:15:09 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 15-12G filed by Akumin Inc.

      15-12G - AKUMIN INC. (0001776197) (Filer)

      2/7/24 6:11:57 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Akumin Inc.

      S-8 POS - AKUMIN INC. (0001776197) (Filer)

      2/7/24 6:09:57 AM ET
      $AKU
      Medical Specialities
      Health Care